e-learning
resources
Vienna 2009
Monday, 14.09.2009
New insights in biology and treatment of pleural tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Soluble mesothelin as a monitoring tool for malignant mesothelioma patients
K. Hollevoet, E. Kellen, K. Nackaerts, L. Bosqueé, P. Germonpré, J. Delanghe, C. Legrand, J. P. van Meerbeeck (Ghent, Leuven, Liège, Antwerp, Louvain-la-Neuve, Belgium)
Source:
Annual Congress 2009 - New insights in biology and treatment of pleural tumours
Session:
New insights in biology and treatment of pleural tumours
Session type:
Oral Presentation
Number:
1798
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Hollevoet, E. Kellen, K. Nackaerts, L. Bosqueé, P. Germonpré, J. Delanghe, C. Legrand, J. P. van Meerbeeck (Ghent, Leuven, Liège, Antwerp, Louvain-la-Neuve, Belgium). Soluble mesothelin as a monitoring tool for malignant mesothelioma patients. Eur Respir J 2009; 34: Suppl. 53, 1798
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma
Source: Annual Congress 2008 - Inorganic dust exposure and the lung
Year: 2008
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma
Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Year: 2012
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008
Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients
Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines
Year: 2009
Integrated CT-PET is a valuable tool for staging malignant pleural mesothelioma
Source: ISSN=ISSN 1810-6838, ISBN=, page=173
Year: 2005
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2006; 28: Suppl. 50, 85s
Year: 2006
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM)
Source: Eur Respir J 2004; 24: Suppl. 48, 81s
Year: 2004
A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma
Source: Eur Respir J 2010; 36: 1099-1105
Year: 2010
Soluble mesothelin as an early diagnostic tool in asbestos-exposed workers
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
Source: Eur Respir J 2013; 41: 18-24
Year: 2013
Prognostic impact of histology and treatment modalities in malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Prognostic characteristics of malignant pleural mesothelioma
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Evaluating the utility of mesothelin in diagnosing mesothelioma
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions
Source: Eur Respir J 2001; 18: Suppl. 33, 397s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept